Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival

J Exp Med. 1994 Jan 1;179(1):341-6. doi: 10.1084/jem.179.1.341.

Abstract

Indefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD / immunology*
  • Antigens, Differentiation, T-Lymphocyte / immunology*
  • CD2 Antigens
  • CD48 Antigen
  • Drug Synergism
  • Female
  • Graft Survival / immunology*
  • Heart Transplantation / immunology*
  • Lymphocyte Culture Test, Mixed
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Inbred CBA
  • Receptors, Immunologic / immunology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Transplantation, Homologous

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Differentiation, T-Lymphocyte
  • CD2 Antigens
  • CD48 Antigen
  • Cd48 protein, mouse
  • Receptors, Immunologic